Analyst Price Targets — BLFS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 27, 2026 11:54 am | — | Stephens | $31.00 | $29.98 | TheFly | BioLife Solutions downgraded to Equal Weight from Overweight at Stephens |
| July 23, 2026 12:32 pm | Matthew Stanton | Jefferies | $31.00 | $31.15 | TheFly | BioLife Solutions downgraded to Hold from Buy at Jefferies |
| July 23, 2026 10:02 am | Yi Chen | H.C. Wainwright | $31.00 | $31.15 | TheFly | BioLife Solutions downgraded to Neutral from Buy at H.C. Wainwright |
| July 23, 2026 5:04 am | — | William Blair | $31.00 | $31.15 | StreetInsider | TD Cowen Downgrades BioLife Solutions (BLFS) to Hold |
| July 22, 2026 6:58 pm | — | Craig-Hallum | $31.00 | $31.15 | TheFly | BioLife Solutions downgraded to Hold from Buy at Craig-Hallum |
| July 22, 2026 2:36 pm | — | Lake Street | $31.00 | $31.20 | TheFly | BioLife Solutions downgraded to Hold from Buy at Lake Street |
| January 5, 2026 2:17 pm | — | Northland Securities | $34.00 | $25.14 | TheFly | BioLife Solutions price target raised, named a 2026 Top Pick at Northland |
| November 24, 2025 11:40 am | Yi Chen | H.C. Wainwright | $32.00 | $26.53 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on BioLife Solutions (BLFS) |
| March 5, 2025 5:11 pm | — | H.C. Wainwright | $30.00 | $26.25 | TheFly | BioLife Solutions price target raised to $30 from $27 at H.C. Wainwright |
| November 15, 2024 12:14 pm | Jacob Johnson | Stephens | $30.00 | $21.58 | StreetInsider | Stephens Reiterates Overweight Rating on BioLife Solutions (BLFS) |
Latest News for BLFS
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Qiagen (NYSE: QGEN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Institutional and Insider Ownership 93.2% of BioLife Solutions shares
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of BioLife Solutions, Inc. (NASDAQ: BLFS) to Repligen Corporation for $11.25 per share in cash and 0.1442 shares of Repligen common stock.Halper Sadeh encourages BioLife shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or…
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and IQVIA (NYSE: IQV - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation. Valuation and Earnings This table compares BioLife Solutions and
BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to break-even earnings per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BLFS.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.